ArticleEndocrine2026
RET p.Cys634-driven progression of hereditary vs. sporadic medullary thyroid cancer.
Article in Endocrine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeConceptually, pitting hereditary mutations, pervading all cells of the body since conception, against the same sporadic mutations, acquired by tumor cells only later in life, could give valuable insights into tumorigenesis and tumor progression. This research sought to explore RET p.Cys634-driven tumorigenesis and progression which, preceding the time of clinical detection, cannot be measured directly.
methodsComparative study of 14 previously untreated index patients with hereditary medullary thyroid cancer (MTC) and 15 previously untreated patients with sporadic MTC who presented with a diagnosis of MTC, for which they underwent initial neck surgery at a tertiary referral center.
resultsAfter Bonferroni correction for multiple testing, only few variables continued to differ significantly between RET p.Cys634-driven hereditary and sporadic MTC: age at thyroidectomy (medians of 33.5 vs. 54 years; P <0.001), and multifocal growth (79 vs. 7%, and medians of 2 foci vs. 1 focus; both P <0.001).
conclusionThe present investigation suggests that tumor progression in MTC before clinical detection is a function of the time passed since tumor onset, whereas tumor onset is defined by the transformatory strength of the RET mutation. This notion, debunking the myth of immanent tumor 'aggressiveness' or "risk" imparted by RET mutations in favor of the concept of genetically encoded tumor onset, emphasizes the need for early diagnosis and intervention, ideally while tumors are still confined to the thyroid.
Indexed as
Identifiers
42257805What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.